Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
about
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.Antibody drug conjugates: lessons from 20 years of clinical experience.Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
P2860
Q33438286-44034BF1-BAD8-4C4C-9646-D3384EC4C338Q38798481-13EECE1A-F57B-4D78-9530-A748F26EFFE2Q38979084-4B8EB81E-1001-4E02-9E87-A344509D72EEQ43525091-AF5F20DD-DDA2-4DBC-9573-69118BAD57C5Q46008308-3DC5007F-F0CB-4529-8BDB-5F9D13DA02DBQ46871150-E29CE53D-34BB-40FC-A927-10EB4F2F166AQ47861842-B4F05A3F-A0FA-44A6-8E17-8ECBD073D0D4Q48234647-8B5013B1-8E01-46AF-A8A0-B1466648E0A9Q52658297-91B99B5A-D4FC-4C14-BD41-FE3A6BC1E993
P2860
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
@ast
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
@en
type
label
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
@ast
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
@en
prefLabel
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
@ast
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
@en
P2093
P2860
P356
P1476
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
@en
P2093
Christopher J Murphy
Joshua Seth Eaton
Mark J Mannis
Paul E Miller
P2860
P304
P356
10.1089/JOP.2015.0064
P577
2015-11-05T00:00:00Z